Section of Neurology - Dr. Ruth Ann Marrie

Professor, Department of Internal Medicine (Neurology), University of Manitoba.

Professor, Department of Community Health Sciences, University of Manitoba

Director, Multiple Sclerosis Clinic

Degrees/Fellowship: MD, PhD, FRCPC

Mailing Address: Health Sciences Centre, GF543, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9

Tel: (204) 787-4951; Fax: (204) 787-1486

E-mail: rmarrie@exchange.hsc.mb.ca

Clinical Interests:
-Multiple sclerosis (MS)
-Neuromyelitis optica.

Research Interests:
My research focuses on various aspects of the epidemiology of MS using a variety of data sources and study designs. I have a particular interest in the impact of comorbid conditions on outcomes in multiple sclerosis, as well as patient-reported outcomes. Other research interests include pediatric MS, etiologic factors for MS, and quality of life.

Recent Publications (as of 2017):

1. Marrie RA, Fisk JD, Stadnyk KJ, Yu BN, Tremlett H, Wolfson C, Warren S, Bhan V. The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Canadian Journal of Neurological Sciences 2013; 40(6):824-831

2. Marrie RA, Bernstein CN, Peschken CA, Hitchon CA, Chen H, Fransoo R, Garland A. Intensive care unit admission in multiple sclerosis: Increased incidence and increased mortality. Neurology 2014; 82(23):2112-2119

3. Marrie RA, Elliott L, Marriott JJ, Cossoy M, Blanchard J, Tennakoon A, Yu N. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014; 83(10): 929-937

4. Yeh EA, Marrie RA, Reginald YA, Buncic JR, Sye A, O’Mahony J, Mah J, Banwell B, Costello FE. Functional-Structural Correlations in the Afferent Visual Pathway in pediatric demyelinating disorders. Neurology 2014; 83(23): 2147-2152

5. Marrie RA, Elliott L, Marriott JJ, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology 2015;84(4):350-358

6. Marrie RA, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold S, Cutter G, Reider N. A Systematic Review of the Incidence and Prevalence of Comorbidity in Multiple Sclerosis: Overview. Multiple Sclerosis Journal 2015; 21(3):253-281

7. Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Leung S, Yu N. Effect of comorbidity on mortality in multiple sclerosis. Neurology 2015;85(3): 240-247

8. McKay KA, Tremlett H, Fisk JD, Patten SB, Fiest K, Marrie RA for the CIHR Team in the Epidemiology and Impact of Comorbidity in Multiple Sclerosis (ECOMS). Adverse health behaviours are associated with depression and anxiety: a prospective multi-site study. Multiple Sclerosis Journal 2015. Aug 5. Epub ahead of print.

9. Fiest KM, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, McKay K, Berrigan L, Marrie RA for the CIHR Team in the Epidemiology and Impact of Comorbidity in Multiple Sclerosis (ECOMS). Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Multiple Sclerosis and Related Disorders 2015; 4(5): 470-476.

10. Marrie RA, Fisk JD, Tremlett H, Wolfson C, Warren S, Tennakoon A, Leung S, Patten SB. Differences in the Burden of Psychiatric Comorbidity in MS Versus the General Population. Neurology 2015;85(22):1972-1979

11. *Fiest K, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, Patten SB, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Singer A, Marrie RA for the CIHR Team “Defining the burden and managing the effects of psychiatric comorbidity in chronic immunoinflammatory disease”. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders 2016; 5: 12-26

12. Marrie RA, Fisk J, Tremlett H, Wolfson C, Warren S, Blanchard J, Patten SB for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurology Clinical Practice. 2016; 6(2): 120-128.

13. Marrie RA, Patten SB, Tremlett H, Wolfson C, Warren S, Svenson LW, Jette N, Fisk JD. Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. Neurology 2016;86(1):1279-1286

14. Razaz N, Joseph KS, Boyce WT, Guhn M, Forer B, Oger J, Marrie RA, Tremlett H. Children of chronically ill parents: relationship between parental multiple sclerosis and childhood developmental health. Multiple Sclerosis Journal 2016;22(11):1452-1462.

15. Zhang T, Tremlett H, Leung S, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell T, Stadnyk K, Yu BN, Marrie RA for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECOMS). Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology 2016; 86(14): 1287-1295.

16. Berrigan L, Fisk F, Patten S, Tremlett H, Wolfson C, Warren S, Fiest K, McKay K, Marrie RA. Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. Neurology 2016.  Epub ahead of print. Mar 9

17. Razaz N, Tremlett H, Marrie RA, Joseph KS. Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children. Multiple Sclerosis Journal 2016; Epub ahead of print. Feb 22 2016

18. Razaz N, Tremlett H, Boyce WT, Guhn M, Marrie RA, Joseph KS. Incidence of mood or anxiety disorders in children of parents with multiple sclerosis. Paediatric and Perinatal Epidemiology. Epub ahead of print. Mar 24 2016

19. McKay KA, Tremlett H, Zhu F, Kastrukoff L, Marrie RA, Kingwell E. A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. European Journal of Neurology 2016; 23(6): 1093-1100.

20. Fiest K, Marrie RA, Jette N, Bennett D. The Standards of Reporting of Neurologic Disorders (STROND) checklist: Application to Multiple Sclerosis. Multiple Sclerosis Journal 2016. Epub ahead of pint. Feb 26 2016

21. Fiest K, Fisk J, Patten S, Tremlett H, Wolfson C, Warren S, McKay K, Berrigan L, Marrie RA. Fatigue and comorbidities in multiple sclerosis. IJMSC 2016; 18(2): 96-104.

22. Salter A, Tyry T, Wang G, Fox RJ, Cutter GR, Marrie RA. Examining the joint effect of disability, health behaviors and comorbidity on mortality in MS. Neurology Clinical Practice 2016;6(5):397-408

23. Wang G, Marrie RA, Salter AR, Fox R, Cofield SS, Tyry T, Cutter GR. Health insurance affects the use of disease-modifying therapy in multiple sclerosis. Neurology 2016; 87(4):365-374

24. Litster B, Fiest KM, Patten SB, Fisk JD, Walker JR, Graff LA, Bolton JM, Marriott JJ, Berrigan LI, Bernstein CN, Zarychanski R, Singer A, Hitchon CA, Peschken CA, Marrie RA. Screening tools for anxiety in persons with multiple sclerosis: A systematic review. IJMSC 2016; 18(6): 273-281

25. Marrie RA, Patten SB, Greenfield J, Svenson L, Jette N, Tremlett H, Wolfson C, Warren S, Profetto-McGrath J, Fisk JD. Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. Brain and Behavior 2016; 6(9):e00493

26. Bethoux F, Marrie RA. A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis. The Patient: Patient-Centered Outcomes Research 2016. May 6. Epub ahead of print.

27. Evans C, Marrie RA, Zhu F, Leung S, Lu X, Melesse DY, Kingwell E, Zhao Y, Tremlett H. Adherence and persistence to drug therapies for multiple sclerosis: a population-based study. MSARD 2016; 8:78-85.

28. Marrie RA, Patten S, Tremlett H, Svenson LW, Wolfson C, Yu BN, Elliott L, Profetto-McGrath J, Warren S, Leung S, Jette N, Bhan V, Fisk JD for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Chronic lung disease and multiple sclerosis: Incidence, prevalence and temporal trends. MSARD 2016;8:86-92

29. *McKay K, Tremlett H, Patten S, Fisk J, Evans C, Berrigan L, Fiest K, Campbell T, Marrie RA for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECOMS).  Determinants of non-adherence to disease-modifying therapies in multiple sclerosis – a cross Canada prospective study. Multiple Sclerosis Journal 2016. Epub ahead of print Jun 29.

30. *Fiest KM, Bernstein CN, Walker JR, Graff LA, Hitchon CA, Peschken CA, Zarychanski R, Abou-Setta A, Patten SB, Sareen J, Bolton J, Marrie RA for the CIHR Team Defining the burden and managing the effects of psychiatric comorbidity in chronic immunoinflammatory disease. Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. BMC Research Notes 2016. Aug 12; 9(1): 404 doi: 10.1186/s13104-016-2204-2

31. Marrie RA, Hall N, Sadovnick AD. Multiple sclerosis in First Nations Canadians: A Pilot Comparison Study. Multiple Sclerosis Journal: Experimental, Translational and Clinical 2016; 2:1-7 doi: 10.1177/2055217316666093

32. Mirsky MM, Marrie RA, Rae-Grant A. Antidepressant treatment in association with multiple sclerosis disease-modifying therapy: Using Explorys in the MS population. IJMSC 2016; 18(6): 305-310

33. Amankwah N, Marrie RA, Bancej C, Garner R, Manuel DG, Wall R, Fines P, Bernier J, Tu K, Reimer K. Multiple sclerosis in Canada 2011 to 2031: Results of a microsimulation modelling study of epidemiological and economic impacts. Health Promotion and Chronic Disease Prevention in Canada. Health Promotion and Chronic Disease Prevention in Canada; 2017:37(2): 37-48

34. Reider N, Salter AR, Cutter GR, Tyry T, Marrie RA. Modifiable factors associated with physical activity in individuals with multiple sclerosis. Research in Nursing and Health 2017;40(2): 143-152

35. Wijnands J, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Marrie RA, Tremlett H. Infection-related health care utilization among people with and without multiple sclerosis. Multiple Sclerosis Journal 2016. Dec 1. Epub ahead of print

36. Bigi S, Marrie RA, Till C, Yeh EA, Akbar N, Feinstein A, Banwell BL. The computer-based symbol digit modality test: age-expected performance in healthy controls and impaired procedural learning in pediatric MS patients. Neurological Sciences 2017; 38(4):635-642

37. Marrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox R. High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology 2017; 88(16):1528-1534

38. Broche BA, Weier K, Longoni G, Fonov VS, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold D, Verhey LHV, Banwell BL, Collins DL. Monophasic demyelination impacts brain growth in children. Neurology 2017; 88(18):1744-1750

39. Marrie RA, Cutter GR, Tyry T, Cofield SS, Fox R, Salter A. Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis. MSARD 2017;13: 87-92. 10.1016/j.msard.2017.02.013

40. Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD. Increased incidence and prevalence of psoriasis in multiple sclerosis. MSARD 2017;13:81-86

41. Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Hogg T, Stadnyk K, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H. Health care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurology 2017;16(6):451-455

42. Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, Leung S, Fiest KM, McKay KA, Fisk JD. Diagnoses of depression and anxiety versus current symptoms and quality of life in MS. IJMSC 2017; Epub ahead of print July 13.

43. Evans C, Marrie RA, Zhu F, Leung S, Lu X, Kingwell E, Zhao Y, Tremlett H. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiology and Drug Safety 2017. Epub ahead of print April 3

44. Garland A, Metz LM, Bernstein CN, Peschken CA, Hitchon CA, Marrie RA. Hospitalization is associated with subsequent disability in multiple sclerosis. MSARD 2017;14:23-28

45. McKay KA, Evans C, Fisk JD, Patten SB, Fiest KM, Marrie RA, Tremlett H. Disease-modifying therapies and adherence in multiple sclerosis: comparing patient self-report with pharmacy records. Neuroepidemiology 2017; 48(3-4):124-130



Dr. Ruth Ann Marrie